[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"neuroendocrine-tumor\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:neuroendocrine-tumor":31},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,46,152,174,206],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100576714","breathing-practice-for-brain-and-mental-health-in-cancer-and-neurodegenerative-diseases-100576714",false,"NCT06788886","Breathing Practice for Brain and Mental Health in Cancer and Neurodegenerative Diseases","Enhancing Brain and Mental Health Through Respiratory Training: Clinical Applications in Cancer and Neurodegenerative Disease Care for Patients and Caregivers (Breathing Study)","Inclusion Criteria:\n\n* STUDY 1: Participants must be physically fit enough to perform light exercise.\n* STUDY 1: Should read and understand English well enough to consent, complete measures, and follow instructions.\n* STUDY 1: Must have access to a smartphone or tablet.\n* STUDY 2: Participants must be physically fit enough to perform light exercise.\n* STUDY 2: Cancer patients may have prostate cancer, neuroendocrine tumor, or brain cancer in any stage.\n* STUDY 2: The main focus is on pairs of cancer patients and their respective caregivers, but individual cancer patients or individual caregivers are also acceptable.\n* STUDY 2: Participants should read and understand English well enough to consent, complete measures, and follow instructions.\n* STUDY 2: They also must have access to a smartphone or tablet.\n* STUDY 3: Participants must be physically fit enough to perform light exercise.\n* STUDY 3: The patient should have multiple sclerosis.\n* STUDY 3: Participants should read and understand English well enough to consent, complete measures, and follow instructions.\n* STUDY 3: They also must have access to a smartphone or tablet.\n\nExclusion Criteria:\n\n* STUDY 1: Participants incompatible with MRI machines due to factors such as pacemakers or metallic implants.\n* STUDY 1: Additionally, those with chronic medical conditions, including heart disease (coronary artery disease, congestive heart failure, hypertension, cardiac arrhythmia), chronic obstructive pulmonary disease (COPD), cystic fibrosis, cancer, diabetes, sleep apnea, aneurysms, and neurological conditions (epilepsy, Alzheimer's disease, Huntington' disease, essential tremor and Parkinson disease) are excluded.\n* STUDY 1: Participants with psychiatric conditions such as psychosis, suicidality, bipolar disorder, major depression, and substance use disorders are excluded.\n* STUDY 1: Participants serving as caregivers for any of the aforementioned conditions and for other illnesses such as cancer or neurological disorders, are also excluded.\n* STUDY 1: Further exclusions apply to those with severe vision, hearing impairments, have a body mass index (BMI) over 30, and those who are pregnant.\n* STUDY 1: Those planning to become pregnant during the study period will be excluded.\n* STUDY 2: Participants incompatible with MRI machines due to factors such as pacemakers or metallic implants are excluded, as are those with chronic lung disease (chronic obstructive pulmonary disease \\[COPD\\], cystic fibrosis), aneurysms, and those who are pregnant.\n* STUDY 2: Those planning to become pregnant during the study period will be excluded.\n* STUDY 3: Participants incompatible with MRI machines due to factors such as pacemakers or metallic implants are excluded, as are those with chronic lung disease (chronic obstructive pulmonary disease \\[COPD\\], cystic fibrosis), aneurysms, and those who are pregnant.\n* STUDY 3: Those planning to become pregnant during the study period will be excluded.",true,"ALL","18 Years","85 Years",{"count":21,"type":22},147,"ESTIMATED","INTERVENTIONAL",[25],"NA","This clinical trial studies the effect of respiratory training for enhancing brain and mental health among patients with multiple sclerosis (MS) and cancer (along with their caregivers). The relationship between respiration, cardiovascular effects in the brain, mental health, and neurophysiological mechanisms are significant for patient populations facing complex health challenges, such as those with cancer and neurodegenerative disease, and their caregivers. By measuring oxygen delivery to brain tissues and cerebrospinal fluid flow, this trial may help researchers investigate the potential benefits of respiratory training for patients with MS and cancer and their caregivers.",[28,29,30,31,32],"Malignant Brain Neoplasm","Malignant Solid Neoplasm","Multiple Sclerosis","Neuroendocrine Tumor","Prostate Carcinoma","RECRUITING","2026-06-08",{"date":36,"type":37},"2026-06-10","ACTUAL",{"date":39,"type":37},"2025-02-05",{"date":41,"type":22},"2027-01-18",{"name":43,"class":44},"Mayo Clinic","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":23,"phases":56,"briefSummary":57,"conditions":58,"keywords":137,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":143,"lastUpdatePostDateStruct":144,"startDateStruct":146,"completionDateStruct":148,"leadSponsor":150,"locationsCount":45},"100432171","virtual-reality-for-gi-cancer-pain-to-improve-patient-reported-outcomes-100432171","NCT04907643","Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes","Randomized Controlled Trial of Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes","Inclusion Criteria:\n\n* Have a primary malignancy of the biliary tract, colon, liver, pancreas, peritoneum, rectum, small intestine, or stomach, with no plan for resection during the study period\n* Tumor types including, but not limited to, adenocarcinoma, squamous cell carcinoma, neuroendocrine tumors, and tumors of mesenchymal origin will be eligible\n* Have clinically significant visceral pain, measured using the standardized NIH PROMIS GI Pain Scale defined as scoring at least 5 points above the nationally normed score\n* Ability to read and write in English\n\nExclusion Criteria:\n\n* Have a condition that interferes with VR usage, including but not limited to seizures, facial injury precluding safe placement of headset, and visual impairments\n* Have cognitive impairment that affects protocol participation. This will be done with a three part cognitive assessment during the initial phone call to assess eligibility followed by consent discussion if eligible.\n* Have brain metastases\n* Have a prognosis of \\\u003C3 months from the time of enrollment per treating oncologist","99 Years",{"count":55,"type":22},360,[25],"Patients with digestive tract malignancy often experience severe and unremitting abdominal pain that negatively affects physical, emotional, and social function, as well as health related quality of life (HRQOL). Therapeutic virtual reality (VR) has emerged as a promising and evidence-based treatment modality for cancer pain. Users of VR wear a pair of goggles with a close-proximity screen in front of the eyes that creates a sensation of being transported into lifelike, three-dimensional worlds. To date, VR has been limited to short-term clinical trials for cancer pain. Moreover, limited research exists on theory-based VR modalities beyond mere distraction, such as VR that employs acceptance and commitment therapy (ACT) with components of biofeedback and mindfulness. To bridge these gaps, this study seeks to: (1) assess the impact of immersive VR on patient-reported outcomes (PROs), including pain, activity metrics, and opioid use among patients with visceral pain from a digestive tract malignancy; (2) assess differences in PROs, activity metrics, and opioid use between skills-based VR therapy vs. distraction VR therapy; and (3) determine patient-level predictors of VR treatment response in visceral cancer pain.\n\nTo address these aims, the study will measure PROs and opioid use in 360 patients randomized among 3 groups and follow them for 60 days after enrollment: (1) an enhanced VR group receiving skills-based VR; (2) a distraction-based VR group receiving patient-selected VR videos; and (3) a VR sham control group using a VR headset with 2-D content. The results will inform best practices for the implementation of VR for visceral cancer pain management and guide selection of patient-tailored experiences.",[59,60,61,62,63,64,65,66,67,68,69,70,71,72,73,74,75,76,77,78,79,80,81,82,83,84,85,86,87,88,89,90,91,92,93,94,95,96,97,98,99,100,101,102,103,104,105,106,107,108,109,110,111,112,113,114,115,116,117,118,119,120,121,122,123,124,125,126,127,128,31,129,130,131,132,133,134,135,136],"Cancer Pain","Visceral Pain","Gastrointestinal Neoplasms","Cancer of Gastrointestinal Tract","Small Intestine Cancer","Pancreas Cancer","Liver Cancer","Colon Cancer","Biliary Tract Cancer","Stomach Cancer","Rectum Cancer","Peritoneal Cancer","Gastrointestinal Cancer Metastatic","Gastrointestinal Cancers - Anus","Gastrointestinal Cancers - Stomach","Gastrointestinal Cancers - Colorectal","Gastrointestinal Cancers - Small Intestine","Small Intestine Cancer Stage III","Small Intestine Cancer Stage IV","Small Intestine Cancer, Recurrent","Pancreas Cancer, Stage III","Pancreas Cancer, Stage IV","Pancreas Cancer, Metastatic","Pancreas Cancer, Recurrent","Liver Cancer Stage IIIa","Liver Cancer Stage IIIb","Liver Cancer Stage IIIc","Liver Cancer Stage IV","Colon Cancer Stage III","Colon Cancer Stage IV","Stomach Cancer Stage III","Stomach Cancer Stage IV","Stomach Cancer Recurrent","Rectum Cancer, Recurrent","Gastrointestinal Cancers - Liver","Anal Cancer","Anal Cancer Stage III","Anal Cancer Stage IV","Anal Cancer Recurrent","Anal Cancer Metastatic","Anal Cancer, Stage IIIA","Anal Cancer, Stage IIIB","Appendix Cancer","Ampullary Cancer","Bile Duct Cancer","Bile Duct Cancer Stage III","Bile Duct Cancer Stage IV","Bile Duct Cancer Stage IVA","Bile Duct Cancer Stage IVB","Bile Duct Cancer Recurrent","Carcinoid Tumor","Carcinoid Tumor of Pancreas","Carcinoid Tumor of Large Intestine","Carcinoid Tumor of GI System","Carcinoid Tumor of Colon","Carcinoid Tumor of Liver","Carcinoid Tumor of Cecum","Carcinoid Tumor of Ileum","Carcinoid Tumor of Rectum","Carcinoid Tumor of the Small Bowel","Carcinoid Tumor of the Stomach","Large Intestine Cancer","Esophagus Cancer","Esophagus Cancer, Stage III","Esophagus Cancer, Stage IV","Esophagus Cancer, Recurrent","Gallbladder Cancer","Gallbladder Cancer Stage III","Gallbladder Cancer Stage IV","Gastric (Stomach) Cancer","Peritoneum Cancer","Rectal Cancer","Esophagus Cancer, Stage I","Esophagus Cancer, Stage II","Gallbladder Cancer Stage I","Gallbladder Cancer Stage II","Bile Duct Cancer Stage I","Bile Duct Cancer Stage II",[138,139,140,141,142],"Virtual Reality","VR","support","GI cancer","cancer pain","2026-02-18",{"date":145,"type":37},"2026-02-20",{"date":147,"type":37},"2021-10-05",{"date":149,"type":22},"2027-03-16",{"name":151,"class":44},"Cedars-Sinai Medical Center",{"id":153,"slug":154,"hasResults":11,"nctId":155,"briefTitle":156,"officialTitle":157,"acronym":4,"eligibilityCriteria":158,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":159,"targetDuration":4,"studyType":23,"phases":161,"briefSummary":163,"conditions":164,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":165,"lastUpdatePostDateStruct":166,"startDateStruct":168,"completionDateStruct":170,"leadSponsor":172,"locationsCount":45},"100603140","early-phase-1-an-investigational-scan-68ga-ga-fapi-04-petct-for-the-imaging-of-patients-with-high-grade-neuroendocrine-cancer-100603140","NCT07132645","An Investigational Scan ([68Ga] Ga-FAPI-04 PET\u002FCT) for the Imaging of Patients With High-Grade Neuroendocrine Cancer","An Exploratory Study of [68Ga]Ga-Fibroblast Activation Protein Inhibitor 4 ([68Ga]Ga-FAPI-04) in Patients With High-Grade Neuroendocrine Neoplasms","Inclusion Criteria:\n\n* Age ≥ 18 years old\n* Current neuroendocrine tumor diagnosis AND high-grade neuroendocrine tumor presentation determined using the following criteria(s):\n\n  * Previous low uptake of \\[68Ga\\] Ga-DOTATATE PET\u002FCT scan OR\n  * Krenning Score ≥ 3 OR\n  * Ki67 index ≥ 20%\n* Able to lie flat for 60 minutes\n* Ability to understand and the willingness to sign a written informed consent\n\nExclusion Criteria:\n\n* Pregnancy or lactation\n* Patient recently underwent surgery with wound healing",{"count":160,"type":22},30,[162],"EARLY_PHASE1","This early phase I trial determines where and to what degree the tracer \\[68Ga\\] Ga-FAPI-04 accumulates in normal and cancer tissues in patients with high grade neuroendocrine cancer. PET is an established imaging technique that utilizes small amounts of radioactivity attached to very minimal amounts of tracer, in the case of this research \\[68Ga\\] Ga-FAPI-04. Because some cancers take up \\[68Ga\\] Ga-FAPI-04, it can be seen with PET. CT utilizes x-rays that traverse body from the outside. CT images provide an exact outline of organs and potential inflammatory tissue where it occurs in patient's body.",[31],"2025-09-22",{"date":167,"type":37},"2025-09-23",{"date":169,"type":37},"2025-09-16",{"date":171,"type":22},"2027-09-01",{"name":173,"class":44},"University of Michigan Rogel Cancer Center",{"id":175,"slug":176,"hasResults":11,"nctId":177,"briefTitle":178,"officialTitle":179,"acronym":180,"eligibilityCriteria":181,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":182,"targetDuration":4,"studyType":23,"phases":184,"briefSummary":186,"conditions":187,"keywords":190,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":196,"lastUpdatePostDateStruct":197,"startDateStruct":199,"completionDateStruct":201,"leadSponsor":203,"locationsCount":205},"100426813","phase-2-intra-arterial-hepatic-iah-infusion-of-radiolabelled-somatostatin-analogs-in-gep-net-patients-with-dominant-liver-metastases-100426813","NCT04837885","Intra-arterial Hepatic (IAH) Infusion of Radiolabelled Somatostatin Analogs in GEP-NET Patients With Dominant Liver Metastases","\"Imaging With 68Ga-DOTA-peptides and Peptide Receptor Radionuclide Therapy With 177Lu-DOTA-peptides of Gastroenteropancreatic Neuroendocrine Tumors: Interest of Intra-arterial Hepatic Infusion in Patients With Dominant Liver Metastases\"","LUTARTERIAL","Inclusion Criteria:\n\n* Histologically proven well differentiated neuroendocrine tumor (NET) of gastrointestinal or pancreatic origin (GEP).\n* Patients are progressive after treatment with cold somatostatin analog (within 12 months according to RECIST), or as soon as the diagnosis is made in case of hepatic invasion \\> 50% without waiting for tumour progression\n* Patient has received 4 standard of care LUTATHERA® cycles\n* Liver Metastatic disease dominant or exclusive and assessable by RECIST 1.1, and not amenable to surgical resection after the last cycle\n* ECOG performance status 0-2\n* Adequate kidney and liver function: creatinine clearance ≥ 50 mL\u002Fmin, ALT\u002FAST ≤ 2,5x the upper limit of normal\n* With no evidence of hematologic alteration after 4 LUTATHERA® cycles: hemoglobin ≥ 8 g\u002FdL, neutrophils ≥ 1500\u002F mm3, platelets ≥ 75.000\u002Fmm3\n* Age ≥ 18 years, no superior limit\n* Contraception required in pre-menopausal female (Intrauterine device, Progestin Pills, Combined Oral Contraceptives, Monthly Injectables, Progestin Injectables, Combined Patch, Combined Vaginal Ring, Female Sterilization, Vasectomy, Implants) and men for at least 6 months after the last LUTATHERA ® injection.\n* Patient´s signed written informed consent\n* Patient affiliated to a social security system\n\nExclusion Criteria:\n\n* Patients with complete response defined by the absence of lesion according to RECIST 1.1 realized during morphological imaging at inclusion (chest-abdomen-pelvis CT scan and hepatic MRI)\n* No residual uptake according to standard 177-Lu scintigraphy performed in the clinical routine 24 hours after each LUTATHERA IV treatment\n* Carcinoid heart disease (LVEF \\\u003C 40%)\n* Dominant or threatening extrahepatic metastases or that may affect vital prognosis\n* Contraindications to intra-hepatic arterial infusion (coagulation disorders, portal thrombosis, intra-hepatic biliary tract dilatation, digestive or biliary anastomosis or fistula, cirrhosis (Child Pugh B8 or C…)\n* Serum albumin \\\u003C30 g\u002FL unless prothrombin time is within the normal range.\n* Heart failure, myocardial infarction, stroke, uncontrolled arterial hypertension under optimal treatment (≥ 160\u002F95 mmHg), pulmonary embolism or revascularization procedure, unstable angina pectoris, uncontrolled cardiac arrhythmia, and clinically significant bradycardia during the last 12 months.\n* Individuals under legal protection or unable of giving their informed consent\n* Pregnancy or breast feeding\n* Currently participating to another clinical research protocol\n* Individuals under legal protection or unable of giving their informed consent\n* MRI scan contraindicated\n* LUTATHERA® contraindicated or toxicity during one of the IV administrations leading to a reduction or cancellation of the following dose",{"count":183,"type":22},23,[185],"PHASE2","The management of liver metastases in neuroendocrine neoplasms is challenging. Peptide receptor radionuclide therapy with radiolabeled somatostatin analogs (SSA) is one of the most promising therapeutic options. As liver is the most frequent site of metastatic disease, our project proposes to compare administration of radiolabeled SSA by arterial intrahepatic infusion (experimental approach) vs intravenous administration (conventional). Evaluation will be made by (i) comparing 68Ga-DOTA-peptides uptake after intra-hepatic versus intravenous route (imaging), (ii) by evaluating the safety of an additional intra-hepatic administration of therapeutic radiolabeled SSA (therapy).",[31,188,189],"Liver Metastases","Neuroendocrine Gastroenteropancreatic Tumour",[191,192,188,193,194,195],"Neuroendocrine tumour","Neuroendocrine gastroenteropancreatic (GEP) tumour","68Ga- DOTA-peptides PET CT","177Lutetium-Octreotate","Peptide Receptor Radionuclide Therapy","2025-07-18",{"date":198,"type":37},"2025-07-23",{"date":200,"type":37},"2021-09-24",{"date":202,"type":22},"2027-03-24",{"name":204,"class":44},"University Hospital, Bordeaux",4,{"id":207,"slug":208,"hasResults":11,"nctId":209,"briefTitle":210,"officialTitle":211,"acronym":4,"eligibilityCriteria":212,"healthyVolunteers":11,"sex":17,"minAge":213,"maxAge":214,"enrollmentInfo":215,"targetDuration":4,"studyType":23,"phases":217,"briefSummary":218,"conditions":219,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":223,"lastUpdatePostDateStruct":224,"startDateStruct":226,"completionDateStruct":228,"leadSponsor":230,"locationsCount":45},"100444575","early-phase-1-18f-mfbg-petct-in-the-evaluation-of-neural-crest-tumor-100444575","NCT05069220","18F-MFBG PET\u002FCT in the Evaluation of Neural Crest Tumor","A Study of 18F-MFBG Imaging for the Tumor Burden Evaluation or Diagnostic Performance in Pheochromocytoma, Paraganglioma and Neuroblastoma.","Inclusion Criteria:\n\n\\- The subject has read, signed, and dated an informed consent form (ICF) prior to any study procedures being performed. Patients with histologically confirmed or clinically suspicious neural crest tumor.\n\nFor patients with neuroblastoma, subject should have a routine clinical 123I-MIBG scintigraphy (planar + SPECT\u002FCT) performed within 6 months prior to the inclusion visit or scheduled within 3 months after the inclusion visit.\n\nThe subject is male or is a nonpregnant, nonlactating female who is either surgically sterile or is post-menopausal. The subject is able and willing to comply with all study procedures as described in the protocol.\n\nExclusion Criteria:\n\n\\- Patients are potentially pregnant (serum and urinary hCG test will be performed in women where pregnancy is not excluded) or is breast-feeding.\n\nPatients undergo surgery between the selection and inclusion visit. Patients who are pregnant, may possibly be pregnant, or wish (including their partners) to become pregnant during the study period, or are lactating. Patients who are not suitable to participate in the trial according to researchers.","1 Year","80 Years",{"count":216,"type":22},150,[162],"The aim of this study is to evaluate the diagnostic performance and tumor burden of 18F-metafluorobenzylguanidine (18F-MFBG) positron emission tomography (PET) in patients with neuroendocrine tumors mainly in pheochromocytoma and paraganglioma (PPGL) and neuroblastoma (NB).",[31,220,221,222],"Neuroblastoma","Pheochromocytoma","Paraganglioma","2024-02-28",{"date":225,"type":37},"2024-03-01",{"date":227,"type":37},"2021-09-01",{"date":229,"type":22},"2026-12",{"name":231,"class":44},"Peking Union Medical College Hospital"]